A new mixture of the two antibodies, known as AZD7442, “statistically significantly reduced the incidence of severe COVID-19 or death” from the disease among non-hospitalized patients who initially developed mild to moderate symptoms, AstraZeneca said in a statement.
The company is conducting a third, final phase of clinical trials of a new antibody preparation to evaluate its safety and efficacy.
“As cases of severe COVID-19 continue worldwide, there is a marked need for new treatments, such as AZD7442, to protect vulnerable populations … that can help prevent progression to serious disease,” said lead researcher Hugh Montgomery.
“These positive results suggest that the right intramuscular dose of AZD7442 could play an important role … in fighting a devastating pandemic,” he stressed.
The study involved 903 people and 90 percent. they belonged to a high-risk group in terms of the development of severe COVID-19.
The AstraZeneca vaccine against COVID-19, developed separately with the University of Oxford, has helped the United Kingdom run a rapid vaccination campaign against the disease.